Friday, May 22, 2009

J&J buy Cougar for abiraterone

Johnson & Johnson has signed an agreement to acquire Cougar Biotechnology for just under $1 billion, a deal which will give it access to the much-touted investigational prostate cancer drug abiraterone.

No comments: